The Testing Evidence for Using Ivermectin for Treating Gastric Cancer or Digestive Cancer
Last Updated on January 5, 2023 by Shaun Snapp
Executive Summary
- Ivermectin is proven to treat a variety of different cancers.
- Gastric cancer or digestive cancer is one of them.
Introduction
In a previous article titled How Ivermectin Is Useful for Treating Cancer we covered the evidence for the benefits of Ivermectin for cancer. But the question of which cancers Ivermectin has been proven to be effective is a constant source of questions.
This article provides an overview coverage of these specific cancers.
Which Cancers Has Ivermectin Been Demonstrated to Trat?
In earlier versions of this article, we were asked which cancers or organs Ivermectin was found to be effective.
There are a lot of quotes in this article, but I have a short one for each cancer type. The article uses the term “IVM” to mean Ivermectin.
Cancer Type #2: Gastric Cancer or Digestive Cancer
Here is the finding of the study Computational Drug Repositioning and Experimental Validation of Ivermectin in Treatment of Gastric Cancer.
Ivermectin Reduces Tumor Size Which Was Associated With Inactivation of WNT/β-Catenin Signaling, Down Regulation of Cell Proliferation and Upregulation of Cell Death Signaling Networks
Ivermectin Inhibits Cell Proliferation and Induces Cell Cycle Arrest.
Nambara’s study showed that IVM could significantly inhibit the proliferation of gastric cancer cells in vivo and in vitro and that the inhibitory effect of IVM depended on the expression of Yes-associated protein 1(YAP1) – NIH
This study was funded by science foundations and hospitals out of Norway.
The Importance of The NIH Stopping Any Funding For Ivermectin Studies
Notice that none of the studies on Ivermectin were performed in the US. The US has by far the largest national medical research budget in the world, and so if the US is not performing studies, this is not only a negative but tells us something peculiar about what the NIH is deciding not to fund in the area of cancer research.
Zero is the number of studies funded by the NIH on Ivermectin. The NIH will not fund studies into generic drugs, as the NIH is controlled by pharmaceutical companies and they have deep financial ties to them. Funding research into generic drugs could end up showing those drugs as effective, which is a threat to pharmaceutical profits, which the NIH is dedicated to maximizing.
Interested in More?
Would you like to get access to 100% independent medical information?
Conclusion
There is now ample evidence that Ivermectin is useful against many different types of cancers. It is unlikely that these are the only cancers for which Ivermectin is effective, but the studies we were able to find so far show that Ivermectin works to combat and prevent. Ivermectin is an immuno-modulator, so it has beneficial effects not only for cancer — as one of the mechanisms of how Ivermectin works are improving the immune system, which means it improves the immune system against cancer as well as other diseases.
Regarding dosage and sourcing of Ivermectin, see the article On the Topic of Ivermectin Dosage and Sourcing.
